Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck Serono, a division of Merck KGaA, has entered into a five year framework agreement with Kadimastem for drug-screening platform to discover new oral drugs to treat multiple sclerosis (MS).
Subscribe to our email newsletter
The new platform developed by Kadimastem permits usage of human functional tissues produced industrially from pluripotent stem cells as a way to search for potential new drugs.
The drug-screening project aims at the discovery of potential oral drugs that act by stimulating myelin repair.
Kadimastem CEO Yossi Ben-Yossef said the undisclosed compensation for the agreement will provide financial support for Kadimastem’s own in-house drug discovery initiatives, in the field of neurodegenerative diseases as well as in the field of Diabetes.
"Kadimastem also produces pancreatic islet cells from pluripotent stem cells, for screening of drugs enhancing insulin secretion and eventually for cellular therapy of Diabetes," Ben-Yossef added.